Open Orphan PLC (AIM:ORPH, OTC:OPORF) CEO Yamin ‘Mo’ Khan joined Proactive's Stephen Gunnion with the news that subsidiary hVIVO has signed a £6.2 million contract with a US-based biotechnology company to test its antiviral candidate using the hVIVO Influenza A human challenge study model.
Open Orphan said the human challenge study is expected to commence in the second half of 2022 and will be conducted at hVIVO’s state-of-the-art facilities in London. It expects the revenue from the contract to be recognised across 2022 and 2023.